News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,833 Results
Type
Article (39649)
Company Profile (247)
Press Release (657937)
Multimedia
Podcasts (48)
Webinars (12)
Section
Business (204143)
Career Advice (2007)
Deals (35414)
Drug Delivery (95)
Drug Development (81034)
Employer Resources (172)
FDA (16173)
Job Trends (14853)
News (345142)
Policy (32529)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (49419)
ALS (87)
Alzheimer's disease (1372)
Antibody-drug conjugate (ADC) (120)
Approvals (16174)
Artificial intelligence (245)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (104)
Biotechnology (175)
Bladder cancer (63)
Brain cancer (26)
Breast cancer (270)
Cancer (2140)
Cardiovascular disease (170)
Career advice (1675)
Career pathing (30)
CAR-T (145)
Cell therapy (406)
Cervical cancer (19)
Clinical research (65897)
Collaboration (814)
Compensation (518)
Complete response letters (19)
COVID-19 (2584)
CRISPR (37)
C-suite (230)
Cystic fibrosis (100)
Data (2088)
Decentralized trials (2)
Denatured (18)
Depression (41)
Diabetes (262)
Diagnostics (6354)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (119)
Drug pricing (97)
Drug shortages (25)
Duchenne muscular dystrophy (92)
Earnings (86411)
Editorial (35)
Employer branding (21)
Employer resources (146)
Events (112047)
Executive appointments (705)
FDA (17378)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (738)
Gene editing (100)
Generative AI (19)
Gene therapy (286)
GLP-1 (702)
Government (4410)
Grass and pollen (4)
Guidances (51)
Healthcare (18811)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (111)
Indications (28)
Infectious disease (2724)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (92)
Interviews (311)
IPO (16499)
IRA (40)
Job creations (3629)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (462)
Leadership (16)
Legal (7908)
Liver cancer (72)
Lung cancer (310)
Lymphoma (146)
Machine learning (5)
Management (58)
Manufacturing (294)
MASH (64)
Medical device (13355)
Medtech (13360)
Mergers & acquisitions (19442)
Metabolic disorders (667)
Multiple sclerosis (77)
NASH (16)
Neurodegenerative disease (83)
Neuropsychiatric disorders (27)
Neuroscience (1886)
NextGen: Class of 2025 (6512)
Non-profit (4477)
Northern California (2580)
Now hiring (39)
Obesity (358)
Opinion (204)
Ovarian cancer (73)
Pain (81)
Pancreatic cancer (81)
Parkinson's disease (146)
Partnered (21)
Patents (227)
Patient recruitment (104)
Peanut (46)
People (57246)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20519)
Phase II (29020)
Phase III (21627)
Pipeline (1132)
Policy (133)
Postmarket research (2563)
Preclinical (8684)
Press Release (64)
Prostate cancer (100)
Psychedelics (30)
Radiopharmaceuticals (245)
Rare diseases (373)
Real estate (5906)
Recruiting (65)
Regulatory (22224)
Reports (46)
Research institute (2319)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (66)
Series A (127)
Series B (83)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2216)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3575)
State (2)
Stomach cancer (13)
Supply chain (67)
Tariffs (32)
The Weekly (28)
United States (22373)
Vaccines (672)
Venture capitalists (41)
Weight loss (231)
Women's health (35)
Worklife (15)
Date
Today (213)
Last 7 days (562)
Last 30 days (2504)
Last 365 days (32814)
2025 (9730)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46539)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (52)
Alaska (7)
Arizona (230)
Arkansas (13)
Asia (37794)
Australia (6179)
California (5896)
Canada (1964)
China (500)
Colorado (258)
Connecticut (265)
Delaware (138)
Europe (81093)
Florida (875)
Georgia (202)
Idaho (57)
Illinois (518)
India (25)
Indiana (305)
Iowa (10)
Japan (157)
Kansas (102)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (868)
Massachusetts (4402)
Michigan (216)
Minnesota (383)
Mississippi (2)
Missouri (80)
Montana (27)
Nebraska (25)
Nevada (60)
New Hampshire (62)
New Jersey (1676)
New Mexico (28)
New York (1684)
North Carolina (948)
North Dakota (7)
Northern California (2580)
Ohio (199)
Oklahoma (14)
Oregon (34)
Pennsylvania (1328)
Puerto Rico (11)
Rhode Island (32)
South America (1096)
South Carolina (21)
South Dakota (1)
Southern California (2216)
Tennessee (101)
Texas (879)
Utah (174)
Virginia (140)
Washington D.C. (61)
Washington State (541)
West Virginia (3)
Wisconsin (52)
697,833 Results for "erasca inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
March 25, 2025
·
4 min read
Press Releases
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
March 20, 2025
·
14 min read
Press Releases
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
January 31, 2025
·
1 min read
Business
Erasca Reports First Quarter 2024 Business Updates and Financial Results
Erasca, Inc. provided business updates and reported financial results for the fiscal quarter ended March 31, 2024.
May 8, 2024
·
10 min read
Press Releases
Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
·
1 min read
Biotech Beach
Erasca to Present at Upcoming Investor Conferences in June 2024
Erasca, Inc. announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one-on-one investor meetings.
May 29, 2024
·
1 min read
Press Releases
Erasca to Present at Upcoming Investor Conferences
November 5, 2024
·
1 min read
Drug Development
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Erasca, Inc. announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor —and provided a pipeline update.
May 16, 2024
·
10 min read
Biotech Beach
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Erasca, Inc. announced the company will present one oral presentation and two poster presentations at the upcoming American Society of Clinical Oncology Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois.
April 24, 2024
·
5 min read
Drug Development
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
Erasca, Inc. today announced the initiation of the global SEACRAFT-2 Phase 3 trial evaluating the pan-RAF inhibitor naporafenib in combination with the MEK inhibitor trametinib (MEKINIST®) in patients with NRAS-mutant (NRASm) melanoma.
June 18, 2024
·
7 min read
1 of 69,784
Next
